Danish university hospital specializing in cardiology, cardio-oncology, and functional disorders within large European clinical research consortia.
Aarhus University Hospital is one of Denmark's largest teaching hospitals, contributing clinical expertise and patient cohorts to European research in cardiology, oncology, neurology, and functional disorders. Their H2020 involvement centers on translating clinical observations into improved diagnostics and treatments — from cardiac risk prediction tools to proton therapy for esophageal cancer. They bring real-world patient data, clinical trial infrastructure, and specialized medical knowledge to multi-partner research consortia across Europe.
PROFID (sudden cardiac death prediction), RESILIENCE (cardiotoxicity from cancer treatment), STOPSTORM (cardiac radioablation), SAMBAfun (accelerometer-based cardiac monitoring), and HARMONIC (cardiac fluoroscopy effects).
PROTECT-trial (proton vs photon therapy for esophageal cancer), RESILIENCE (cardio-oncology intersection), and HARMONIC (paediatric radiotherapy dose optimization).
ETUDE (functional disorders training network), DOLORisk (neuropathic pain), TENSION (stroke thrombectomy), and AD Detect-Prevent (Alzheimer's detection).
ImmUniverse (multi-omics for atopic dermatitis and ulcerative colitis), SUPPORT-E (COVID-19 convalescent plasma), and HIVACAR (HIV functional cure).
FEMaLe (machine learning for endometriosis detection), VEMoS (virtual eye model with neural networks), and See Far (smart glasses for visual loss).
AMELIE (anchored muscle cells for faecal incontinence) and TENSION (extended-window stroke thrombectomy).
In the early period (2015–2018), AUH's work was broadly distributed across neurology, virology, ophthalmology, and geriatric conditions — including HIV vaccines, stroke treatment, Alzheimer's detection, and digital brain games. From 2019 onward, a clear concentration emerged around cardiology and cardio-oncology, with multiple projects addressing cardiac risk, heart failure from cancer drugs, cardiac radioablation, and proton therapy. They also moved toward data-driven and multi-omics approaches for immune-mediated and functional disorders.
AUH is consolidating around the cardiology–oncology intersection and precision medicine approaches, making them an increasingly focused partner for cardiac risk, radiation therapy, and immune profiling projects.
AUH operates exclusively as a participant or third party — they have never coordinated an H2020 project, which is typical for a hospital contributing clinical expertise and patient access rather than leading research design. With 228 unique partners across 29 countries, they connect into large, diverse consortia. This broad network makes them a well-connected clinical validation partner who can plug into almost any European health research consortium.
AUH has collaborated with 228 unique partners across 29 countries, indicating deep integration into the European clinical research landscape. Their network spans nearly all EU member states, with no apparent geographic concentration beyond a natural Nordic base.
AUH sits at the intersection of cardiology and oncology — a niche (cardio-oncology) that few European hospitals cover with this depth in EU-funded research. Their dual strength in cardiac risk assessment and radiation therapy effects positions them uniquely for projects studying treatment side effects and long-term patient outcomes. For consortium builders, they offer something hard to find: a large teaching hospital with active clinical cohorts, multi-omics capability, and a track record of contributing to 18 H2020 projects without the overhead of being a coordinator.
